SK바이오팜

326030KOSPI

64.3 / 100

Reference Date: 2026-09-08

Financial Score26.5 / 40

News Sentiment19.8 / 25

Momentum9.0 / 20

Disclosure9.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but PBR raises overvaluation concerns. Roughly flat over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

SK Bios制药 was established in 1993, focusing on innovative drug development for epilepsy and successfully expanding its technology exports to multiple countries, including the U.S. and Europe. Its flagship products, Xenobamate and Solriamfetol, are sold in global markets, with sales reaching 70.67 billion KRW in 2025. The company is also advancing into new therapeutic modalities such as RPT and TPD to expand into oncology.

Number of Employees

272people

Average Salary

109.0M KRW

Score Calculation Basis

Detailed Financial Score

PER

24.93Industry Average 15.001.5Point

1.7x industry avg (risky)

PBR

8.06Industry Average 1.200.0Point

6.7x industry avg (risky)

ROE

36.17Industry Average 8.007.0Point

4.5x industry avg (excellent)

Debt Ratio

9.30Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~202510.0 / 10 points

Revenue Growth Rate

3.0 / 3

Avg ▲41.7% (2-year basis)

Operating Profit Growth Rate

3.0 / 3

Avg ▲234.2% (2-year basis)

ROE Trend

4.0 / 4

Avg ROE 25.3% (improving, 3yr)

Detailed News Sentiment

29 totalPositive 25Neutral 4Negative 0Average Sentiment Score 79.3

Positive
SK·엔비디아 ‘AI 동맹’ 바이오로 확장… SK바이오팜, B200 1...
SK바이오팜이 엔비디아와의 협력으로 AI 기반 신약 개발 인프라를 강화하여 기술적 우위와 투자 확대를 통해 긍정적인 시장 반응을 이끌어낼 것으로 예상됩니다.
Positive
SK바이오팜, 4억달러 베팅의 승부처…‘두 번째 엑스코프리’보다 큰.....
SK바이오팜의 새로운 뇌전증 신약 후보물질이 기존 엑스코프리보다 더 큰 잠재력을 보여주며 긍정적인 투자 전망을 제공합니다.
Positive
SK바이오팜에 GPU 128장 공급…베슬AI, 제약·바이오로 확장
SK바이오팜과의 GPU 공급 계약으로 베슬AI의 기술 확장이 기대되어 긍정적 영향 예상.

Detailed Momentum

52-week position1.0Point

Near 52w low (15%, downtrend)

Current 85,000Won52-week high 140,70052-week low 74,600

1-month return3.0Point

1m -0.47% (flat)

Volume trend5.0Point

Volume increasing

Detailed Disclosure

10 totalPositive 1Neutral 8Negative 1

Neutral최대주주등소유주식변동신고서2026-08-31
Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-08-31
Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-08-31
Neutral대규모기업집단현황공시[분기별공시(개별회사용)]2026-08-27
Neutral투자판단관련주요경영사항 (뇌전증 신약 후보 물질 Opakalim 등에 대한 라이선스 인 계약)2026-08-26